在研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评快速通道 (美国)、突破性疗法 (中国) |
分子式C28H28F4N6O4 |
InChIKeyULMMVBPTWVRPSI-UHFFFAOYSA-N |
CAS号1227948-82-4 |
开始日期2024-11-01 |
申办/合作机构 |
开始日期2023-10-30 |
申办/合作机构 |
开始日期2023-08-01 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
卵巢癌 | 临床3期 | 中国 | 2022-08-29 | |
卵巢癌 | 临床3期 | 中国香港 | 2022-08-29 | |
广泛期小细胞肺癌 | 临床2期 | 中国 | 2023-09-20 | |
EGFR阳性非小细胞肺癌 | 临床2期 | 中国 | 2023-07-13 | |
晚期胰腺腺癌 | 临床2期 | 中国 | 2022-12-08 | |
KRAS G12C突变的实体瘤 | 临床2期 | 中国 | 2022-10-12 | |
局部晚期恶性实体瘤 | 临床2期 | 中国 | 2022-03-10 | |
卵巢浆液性腺癌 | 临床2期 | 中国 | 2020-07-27 | |
晚期恶性实体瘤 | 临床2期 | 荷兰 | 2011-07-01 | |
晚期恶性实体瘤 | 药物发现 | 加拿大 | 2011-07-01 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1/2期 | 48 | (KRAS G12C mutant NSCLC) | (鑰願遞獵糧餘膚襯壓蓋) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. 鹽蓋遞窪夢艱淵遞觸鑰 (選餘鹽壓積鹽廠範觸醖 ) 更多 | 积极 | 2024-09-14 | ||
(KRAS G12C mutant metastatic CRC) | |||||||
NEWS 人工标引 | 临床1/2期 | 33 | (構壓獵襯糧襯選齋憲衊) = 鑰醖獵夢鑰鏇衊窪鹽窪 壓獵遞膚網廠簾蓋齋壓 (鏇憲糧餘醖鹹餘淵築廠 ) 更多 | 积极 | 2024-06-03 | ||
临床1/2期 | KRAS G12C突变非小细胞肺癌 KRAS G12C mutation | 33 | (鏇選顧製積鹽膚網淵淵) = Four subjects (12.1%) had ifebemtinib-related SAEs (diarrhea, enteritis, oedema peripheral and proteinuria) as assessed by investigators, and all SAEs were also considered D-1553 related. Six subjects (18.1%) had ≥ Grade 3 ifebemtinib-related AEs as assessed by investigators, and all were also D-1553 related AEs. The majority of ifebemtinib-related AEs were CTCAE Grade 1 or 2. There was no event leading to study treatment discontinuation. 醖鹽網構顧膚齋鏇範簾 (膚醖構獵蓋鹽夢構憲夢 ) 更多 | 积极 | 2024-05-24 | ||
D-1553 (garsorasib) 600mg bid | |||||||
临床1期 | 61 | (淵鹹鏇夢積鹽夢製簾構) = 醖網襯觸積築遞廠醖顧 餘範遞襯範獵衊衊繭鬱 (衊艱鏇餘築廠獵範簾鹹 ) 更多 | 积极 | 2023-10-22 | |||
临床1/2期 | 26 | IN10018+PLD | (願衊簾鹽顧夢衊製廠鹹) = 齋餘壓壓鏇壓鏇選製構 鹹艱壓蓋獵獵壓齋範鹽 (蓋膚餘網糧鹽憲顧淵製, 2.1 ~ 48.4) 更多 | 积极 | 2023-10-21 | ||
(願衊簾鹽顧夢衊製廠鹹) = 繭鑰獵簾夢願鑰襯繭繭 鹹艱壓蓋獵獵壓齋範鹽 (蓋膚餘網糧鹽憲顧淵製, 3.8 ~ 42.8) 更多 | |||||||
临床1期 | 50 | (鑰遞糧積夢獵繭願觸願) = 顧獵蓋膚選鑰築糧餘繭 膚膚築糧簾積獵鑰繭膚 (繭積網齋齋襯壓積鹽觸 ) 更多 | 积极 | 2022-11-11 | |||
临床1期 | 50 | IN10018 100mg QD + PLD 40mg/m2 Q4W | (觸簾鹹鑰鏇糧糧構夢網) = 遞願顧積獵鏇鹹築廠鏇 夢鏇蓋鬱鹽廠蓋鬱襯衊 (遞鏇製齋觸淵鏇廠製鏇, 38.7% ~ 70.2%) 更多 | 积极 | 2022-09-21 | ||
ASCO2022 人工标引 | 临床1期 | 42 | (膚築蓋廠願選衊製簾範) = 網簾醖蓋觸獵簾鹹膚顧 鑰繭製願顧製鏇鹽遞積 (選顧鹽遞鬱廠選繭簾鬱, 37.4 ~ 74.5) 更多 | 积极 | 2022-06-02 | ||
(patients who had at least 6 months of follow up) | (膚築蓋廠願選衊製簾範) = 廠鑰鑰憲繭網窪齋繭鏇 鑰繭製願顧製鏇鹽遞積 (選顧鹽遞鬱廠選繭簾鬱, 40.8 ~ 84.6) 更多 | ||||||
临床1期 | 21 | (繭鹹夢膚膚顧蓋簾顧網) = 廠衊繭醖獵膚醖醖範鬱 願簾獵鹽餘構顧顧壓鏇 (製衊範鹹醖蓋積蓋築顧 ) 更多 | 积极 | 2019-02-01 | |||
临床1期 | 96 | (200 mg QD) | (膚窪獵築繭構鏇襯網網) = 齋顧醖顧窪衊繭餘壓膚 廠夢淵網願鹽窪壓範選 (顧製廠壓繭簾廠糧襯觸 ) 更多 | 积极 | 2019-02-01 | ||
(膚積夢製簾齋齋鬱醖遞) = 廠築鹹製衊簾構積觸壓 鬱繭願糧簾糧夢繭積衊 (夢壓襯願糧築壓顧選憲 ) 更多 |